The striking response of a patient with metastatic HER2-amplified and L755S-mutated breast cancer to T-DM1 and DS8201, after showing resistance to other HER2-targeted drugs, exemplifies the specific anticancer potential of anti-HER2 ADCs (26). This evidence concerns the gene ERBB2 and breast cancer.